These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22140532)

  • 21. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
    Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
    J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
    Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
    Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
    Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
    Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
    Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
    Goldberg L; Tijssen MR; Birger Y; Hannah RL; Kinston SJ; Schütte J; Beck D; Knezevic K; Schiby G; Jacob-Hirsch J; Biran A; Kloog Y; Marcucci G; Bloomfield CD; Aplan PD; Pimanda JE; Göttgens B; Izraeli S
    Blood; 2013 Oct; 122(15):2694-703. PubMed ID: 23974202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
    Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ
    Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Tomlins SA; Rhodes DR; Perner S; Dhanasekaran SM; Mehra R; Sun XW; Varambally S; Cao X; Tchinda J; Kuefer R; Lee C; Montie JE; Shah RB; Pienta KJ; Rubin MA; Chinnaiyan AM
    Science; 2005 Oct; 310(5748):644-8. PubMed ID: 16254181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
    Ha S; Iqbal NJ; Mita P; Ruoff R; Gerald WL; Lepor H; Taneja SS; Lee P; Melamed J; Garabedian MJ; Logan SK
    Oncogene; 2013 Aug; 32(34):3992-4000. PubMed ID: 22986532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
    Sun C; Dobi A; Mohamed A; Li H; Thangapazham RL; Furusato B; Shaheduzzaman S; Tan SH; Vaidyanathan G; Whitman E; Hawksworth DJ; Chen Y; Nau M; Patel V; Vahey M; Gutkind JS; Sreenath T; Petrovics G; Sesterhenn IA; McLeod DG; Srivastava S
    Oncogene; 2008 Sep; 27(40):5348-53. PubMed ID: 18542058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
    Mounir Z; Korn JM; Westerling T; Lin F; Kirby CA; Schirle M; McAllister G; Hoffman G; Ramadan N; Hartung A; Feng Y; Kipp DR; Quinn C; Fodor M; Baird J; Schoumacher M; Meyer R; Deeds J; Buchwalter G; Stams T; Keen N; Sellers WR; Brown M; Pagliarini RA
    Elife; 2016 May; 5():. PubMed ID: 27183006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
    Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.
    Kim J; Wu L; Zhao JC; Jin HJ; Yu J
    Oncogene; 2014 Oct; 33(44):5183-92. PubMed ID: 24186205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
    Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
    Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.